24/10-2017 
 
www.healthanddisease.com
Search in Muscles and Joints
 
 
 
 
 
Muscles and Joints
Test yourself
Back and neck problems
Arthritis
Connective tissue
Bone tissue diseases
Injuries
Muscles and tendons
Joint replacements - artificial joints
Health news
Breast Cancer: Not One Disease but 10 - 11-05-2012
Music prevents organ rejection - 03-05-2012
Gel to boost male fertility - 18-04-2012
Arthritis sufferers 40 per cent more likely to develop fatal heart problems - 14-03-2012
Youngest in school year more likely to be diagnosed with ADHD - 12-03-2012
Dementia is next global health time bomb - 09-03-2012
Vitamin E may be bad for bones - 07-03-2012
Vitamin D Lower Stress Fracture Risk in Girls - 06-03-2012
Dust in offices can change your hormones - 05-03-2012
New skin cancer drug prolong life - 29-02-2012
Fibers in the fight against bowel disease - 28-02-2012
Older mothers may be more prone to depression than younger women - 23-02-2012
Alcohol releases addictive endorphins, study shows - 21-02-2012
Human stem cell therapy works in blind patients in first trial - 08-02-2012
Cancer slowed by cooked tomatoes - 06-02-2012
Nicotine replacement has no long-term benefit when quitting smoking
Scientists grow sperm in laboratory dish
Anti-depressant use up by a quarter since credit crunch
Chronic Pain in Children and Adolescents Becoming More Common
Few Parents Recall Being Told by Doctors That Their Child Is Overweight
Kids Born Just a Few Weeks Early at Risk of Behavioral Problems
New super vaccine could tackle 70% of lethal cancers

New skin cancer drug prolong life

A study of a new drug for advanced skin cancer has shown it almost doubles survival times, The drug, called vemurafenib, was tested in a clinical trial that examined its impact on tumour size and survival in patients with advanced melanoma skin cancer that had spread to other parts of the body.
 

Patients live longer
 

The outlook for this type of cancer is generally poor as it's an aggressive cancer with few treatment options and patients tend to survive for less than a year. Researchers found that approximately half of the patients responded to the drug and that the overall survival rate in these patients was nearly 16 months, on average.
 

Better outlook for patients with genetic mutation
 

This study provides evidence on the effectiveness of a new drug, vemurafenib, for treating some patients with metastatic melanoma. Because the drug works by targeting a specific genetic mutation, it won’t be suitable for patients who aren’t carrying the mutation, which is found in around half of patients with melanoma that has spread.
The drug has not yet been approved in Europe
 

Read mere on NHS Choices

Test yourself
Back and neck problems
Arthritis
Connective tissue
Bone tissue diseases
Injuries
Muscles and tendons
Joint replacements - artificial joints
Health news
Copyright - Generic - 2010